title: How I treat patients with relapsed chronic lymphocytic leukaemia.
abstract: As front line therapy has improved, the treatment of relapsed chronic lymphocytic leukaemia has become more difficult as the disease becomes resistant and the patient accumulates comorbidities. The outcome for those who relapse after immunochemotherapy with fludarabine, cyclophosphamide and rituximab is strongly influenced by the duration of initial response. Patients who relapse within the first year or with a TP53 abnormality have very high-risk disease and will not respond to chemotherapy. High dose glucocorticoid and alemtuzumab followed by an allogeneic stem cell transplant is probably the best approach for younger, fitter patients in this category. Those who relapse after 2-3 years without TP53 abnormality will probably respond to their initial therapy again. Relapse within 12-24 months carries an intermediate outlook. Additional options include bendamustine and rituximab, ofatumumab and lenalidomide. New therapies are on the horizon and patients should be discussed with a specialist centre and entered into a clinical trial whenever possible.
authors.affiliation: Department of Haematological Medicine, Kings College, London, UK.
authors.forename: Kirsty
authors.initials: K
authors.lastname: Cuthill
authors.forename: Stephen
authors.initials: S
authors.lastname: Devereux
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
keywords: chronic lymphocytic leukaemia; leukaemia therapy; refractory CLL; relapsed CLL